International Journal of Alzheimer’s Disease

Tau Protein: Function and Pathology


Publishing date
20 Jul 2012
Status
Published
Submission deadline
20 Jan 2012

Lead Editor

1Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Ein Karem, Jerusalem 1120, Israel

2INSERM U837, "Alzheimer & Tauopathies", Jean-Pierre Aubert Research Centre, University of Lille-Nord de France, UDSL, France

3Departments of Neurology and Neuroscience and Cell Biology, George and Cynthia Mitchell Center for Neurodegenerative Diseases, The University of Texas Medical Branch, Galveston, TX, USA

4Brain and Mind Research Institute, University of Sydney, Camperdown, NSW 2050, Australia


Tau Protein: Function and Pathology

Description

In the last decade, the fundamental role of the microtubule-associated tau protein in neurodegeneration and dementia has been widely accepted. It is now well established that its pathological forms (hyperphosphorylated, aggregated) are a major cause of dementia, rather than being only a secondary effect to the amyloid plaques in Alzheimer's disease (AD). Much evidence has been accumulated pointing to the contribution of tau to pathology by two mechanisms: loss of function (such as stabilization of microtubules) as well as gain of toxic function (aggregation, oligomer formation, and/or deposition as neurofibrillary tangles). Recent studies have contributed new concepts towards our understanding of the pathogenesis of tau pathology, such as the identification of toxic soluble oligomers of tau, existence of extracellular forms as factor influencing tangle propagation, and the responsiveness of tau pathological forms to environmental stimuli. This emerging data leading to a better understanding of tau pathogenesis, together with the disappointing results of antiamyloid therapeutic approaches against AD, have led the scientific community to devote much more effort into studying tau pathology and to develop tau-targeted therapeutic approaches.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts towards understanding tau pathology in AD and other tauopathies (from various aspects, including molecular, immunological, biochemical, pathological ,and behavioral), as well as unravel the physiological functions of tau, in an effort to develop new treatments. Potential topics include, but are not limited to:

  • Tau and amyloid relationship
  • Physiological functions of tau
  • Toxic functions of tau
  • Intracellular versus extracellular tau in disease pathogenesis
  • Tau and microglia
  • Tau and environmental stimuli
  • Unique animal models for tau pathology
  • Therapeutic approaches targeting tau pathology
  • Diagnostic tools and biomarkers for tau pathology

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 707482
  • - Editorial

Tau Protein: Function and Pathology

Hanna Rosenmann | David Blum | ... | Lars M. Ittner
  • Special Issue
  • - Volume 2012
  • - Article ID 251426
  • - Review Article

Protein Tau: Prime Cause of Synaptic and Neuronal Degeneration in Alzheimer's Disease

Natalia Crespo-Biel | Clara Theunis | Fred Van Leuven
  • Special Issue
  • - Volume 2012
  • - Article ID 873270
  • - Review Article

Lessons from Tau-Deficient Mice

Yazi D. Ke | Alexandra K. Suchowerska | ... | Lars M. Ittner
  • Special Issue
  • - Volume 2012
  • - Article ID 406561
  • - Review Article

MicroRNAs and the Regulation of Tau Metabolism

Sébastien S. Hébert | Nicolas Sergeant | Luc Buée
  • Special Issue
  • - Volume 2012
  • - Article ID 970980
  • - Review Article

Drosophila Models of Tauopathies: What Have We Learned?

Marc Gistelinck | Jean-Charles Lambert | ... | Pierre Dourlen
  • Special Issue
  • - Volume 2012
  • - Article ID 493670
  • - Research Article

Tau and Caspase 3 as Targets for Neuroprotection

Anat Idan-Feldman | Regina Ostritsky | Illana Gozes
  • Special Issue
  • - Volume 2012
  • - Article ID 731526
  • - Review Article

Structure and Pathology of Tau Protein in Alzheimer Disease

Michala Kolarova | Francisco García-Sierra | ... | Daniela Ripova
  • Special Issue
  • - Volume 2012
  • - Article ID 578373
  • - Review Article

Tau Phosphorylation by GSK3 in Different Conditions

Jesús Avila | Gonzalo León-Espinosa | ... | Javier DeFelipe
International Journal of Alzheimer’s Disease
 Journal metrics
Acceptance rate17%
Submission to final decision100 days
Acceptance to publication36 days
CiteScore3.800
Impact Factor-
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.